Oncotarget

Clinical Research Papers:

High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma

Haijian Zhang, Yidong Liu, Huyang Xie, Weisi Liu, Qiang Fu, Dengfu Yao _, Jiejie Xu and Jianxin Gu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:59777-59790. https://doi.org/10.18632/oncotarget.15894

Metrics: PDF 1095 views  |   HTML 1710 views  |   ?  


Abstract

Haijian Zhang1,2,*, Yidong Liu1,*, Huyang Xie3,*, Weisi Liu1, Qiang Fu1, Dengfu Yao2, Jiejie Xu1 and Jianxin Gu1

1 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

2 Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Jiangsu, China

3 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Dengfu Yao, email:

Jiejie Xu, email:

Jianxin Gu, email:

Keywords: mucin 5AC, clear-cell renal cell carcinoma, overall survival, recurrence-free survival, prognostic biomarker

Received: December 21, 2016 Accepted: February 23, 2017 Published: March 04, 2017

Abstract

Background: Mucin 5AC (MUC5AC), as a member of secreted/gel-forming mucin family, was frequently found to be abnormally expressed in inflammation or malignant diseases. However, the clinic pathologic features and prognostic values of MUC5AC in clear-cell renal cell carcinoma (ccRCC) have not been reported up to now.

Methods: MUC5AC expression was analyzed by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves, Univariate and Multivariate Cox analysis and newly-established nomogram model were performed to evaluate the prognostic value.

Results: MUC5AC expression was firstly found to be up-regulated in patients with ccRCC, positively associated with tumor size, pN stage, lymphovascular invasion, Fuhrman grade, rahbdoid differentiation, sarcomatoid features, tumor necrosis, ECOG-PS and recurrence. Furthermore, MUC5AC expression might be contributed to risk stratification of ccRCC patients with TNM stage III+IV or Fuhrman grade 3 or 4 for overall survival (OS) and recurrence-free survival (RFS) analysis, and it was demonstrated to be negatively correlated with OS and RFS of ccRCC patients. What’s more, MUC5AC was identified as a potential independent adverse prognostic factor; prediction accuracy of MUC5AC-based new nomogram model was drastically improved for OS and RFS of ccRCC patients.

Conclusion: MUC5AC is a promising independent adverse prognostic factor for ccRCC patients, it maybe conducive to postoperative risk stratification and guide treatment in the future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15894